Role of LMO7 in atherosclerosis
LMO7 在动脉粥样硬化中的作用
基本信息
- 批准号:10670757
- 负责人:
- 金额:$ 53.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:Apolipoprotein EApoptosisArterial Fatty StreakArteriesAtherosclerosisCardiovascular DiseasesCarotid EndarterectomyCd68CellsCharacteristicsCholesterolCirculationCollagenDataDependenceEventExhibitsExtracellular MatrixFeedbackFunctional disorderGene ExpressionGenesHigh Fat DietHumanIn VitroInflammationInflammatoryInvestmentsKnock-outKnockout MiceLIM DomainLIM Domain ProteinLesionLipidsMapsMetalloproteasesMethodsModelingMolecularMorbidity - disease rateMorphologyMusMyocardial InfarctionNecrosisPathway interactionsPeripheral Vascular DiseasesPhenotypePlayProliferatingProteinsRepressionResolutionRoleRuptureSamplingSignal PathwaySignal TransductionSmooth MuscleSmooth Muscle MyocytesSpecimenStainsStrokeTestingTherapeuticThickThinnessVascular Smooth Muscleatheroprotectiveatherosclerotic plaque rupturebiobankcomparison controlcoronary plaquein vivoinsightloss of functionmRNA Expressionmolecular imagingmortalitynovelpreventsingle-cell RNA sequencingtranscription factortransdifferentiationvascular injurywound healing
项目摘要
Role of LMO7 in atherosclerosis Atherosclerosis is a major cause of cardiovascular disease morbidity and
mortality, including myocardial infarction (MI), stroke, and peripheral vascular disease. As plaque rupture is a
key factor in atherothrombotic events, understanding the determinants of plaque stability is critical. The
underlying molecular mechanisms are poorly understood, but thin cap fibroatheromas, characterized by
inflammation, matrix metalloprotease (MMP) activity, large necrotic cores, and thin fibrous caps, are considered
more vulnerable to rupture. Vascular smooth muscle cells (SMC) play a critical role in plaque stabilization by
forming the fibrous cap that covers the lipid-laden plaque and necrotic core. Recent studies have revealed the
paradigm-changing findings that SMC comprise a greater portion of the plaque interior than previously
appreciated by transdifferentiating to phenotypes that lack SMC markers, and that investment of the
plaque by SMC-derived cells appears to be atheroprotective. Thus, SMC play a central role in regulating
both plaque size and stability.
Multiple lines of evidence support a protective role for TGF signaling in plaques. We have recently
identified the protein LIM Domain Only 7 (LMO7) as a key negative feedback regulator of TGF signaling in SMC
that promotes wound healing resolution (Xie et al, Circulation, 2019). Mice with global or inducible smooth
muscle-specific knockout of LMO7 (SM-LMO7-/-) exhibit enhanced TGF signaling and extracellular matrix
(ECM) synthesis compared to controls following vascular injury. We find that LMO7 represses the TGF pathway
at multiple levels. In new studies, we demonstrate that SM-LMO7-/- mice develop plaques of similar size but
with features of increased stability compared to controls in the ApoE-/- high fat diet (HFD) model. The SM-
LMO7-/- plaques have reduced necrotic core size, decreased CD68+ cells, increased ACTA2 and collagen
staining, and thicker fibrous caps. Preliminary lineage tracing data in these mice reveals that SM-LMO7-/-
increases the number of transdifferentiated SMC-derived cells in lesions, a phenotype that may be protective.
Preliminary data in human carotid specimens reveals that LMO7 mRNA expression is increased 5.6X in plaque
vs normal artery, and is enriched in ruptured vs non-ruptured lesions. We hypothesize that LMO7 loss of function
in SMC promotes more stable plaques in mice and humans. In Aim 1, we will determine the role of SMC LMO7
in plaque composition and gene expression using comprehensive staining and single cell RNA-sequencing
analyses. In Aim 2, we will dissect underlying mechanisms, and in Aim 3, we directly test the role of SMC LMO7
in lesion stability by assessing plaque rupture in mice, as well as LMO7 expression and localization in human
ruptured vs stable lesions. These studies will provide insights into the pathophysiology of atherosclerotic plaque
remodeling with potential therapeutic implications.
LMO7在动脉粥样硬化中的作用动脉粥样硬化是心血管疾病发病率和
死亡率,包括心肌梗塞(MI)、中风和外周血管疾病。因为斑块破裂是一种
在动脉粥样硬化血栓形成事件中的关键因素,了解斑块稳定性的决定因素至关重要。这个
潜在的分子机制知之甚少,但薄帽纤维动脉粥样硬化瘤的特征是
炎症、基质金属蛋白酶(MMPs)活性、大的坏死核和薄的纤维帽被考虑在内。
更容易破裂。血管平滑肌细胞(SMC)通过以下途径在斑块稳定中发挥关键作用
形成覆盖富含脂质的斑块和坏死核心的纤维帽。最近的研究表明,
与以前相比,SMC在斑块内部所占的比例更大,这一改变范式的发现
通过向缺乏SMC标记的表型的转化而受到赞赏,以及
SMC来源的细胞形成的斑块似乎具有动脉粥样硬化保护作用。因此,SMC在调节中起着核心作用
斑块大小和稳定性。
多条证据支持斑块中转化生长因子信号的保护作用。我们最近做了
LIM结构域7(Lmo7)是转化生长因子信号的负反馈调节因子
这促进了伤口愈合的解决(谢等人,《循环》,2019年)。具有全局或可诱导平滑的小鼠
肌肉特异性敲除Lmo7(SM-Lmo7-/-)增强转化生长因子信号和细胞外基质
血管损伤后(ECM)合成与对照组比较。我们发现Lmo7抑制转化生长因子途径
在多个层面上。在新的研究中,我们证明了SM-LMO7-/-小鼠出现了类似大小的斑块,但
与ApoE/高脂饮食(HFD)模型中的对照组相比,该模型具有更高的稳定性。SM-
LMO7-/-斑块缩小了坏死灶的大小,减少了CD68+细胞,增加了ACTA2和胶原
染色,纤维帽较厚。这些小鼠的初步谱系追踪数据显示,SM-LMO7-/-
增加病变中转分化的SMC来源细胞的数量,这是一种可能具有保护性的表型。
人颈动脉标本的初步数据显示,LMO7mRNA在斑块中的表达增加了5.6倍
VS正常动脉,并在破裂病变与未破裂病变中丰富。我们假设LMO7功能丧失
在SMC中,促进小鼠和人类体内更稳定的斑块。在目标1中,我们将确定SMC LMO7的作用
斑块组成和基因表达的综合染色和单细胞RNA测序
分析。在目标2中,我们将剖析潜在的机制,在目标3中,我们直接测试SMC LMO7的作用
通过评估小鼠斑块破裂以及LMO7在人类中的表达和定位来影响病变的稳定性
破裂病变与稳定病变。这些研究将为动脉粥样硬化斑块的病理生理学提供深入的认识。
具有潜在治疗意义的重塑。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The age of bone marrow dictates the clonality of smooth muscle-derived cells in atherosclerotic plaques.
- DOI:10.1038/s43587-022-00342-5
- 发表时间:2023-01
- 期刊:
- 影响因子:0
- 作者:Kabir, Inamul;Zhang, Xinbo;Dave, Jui M. M.;Chakraborty, Raja;Qu, Rihao;Chandran, Rachana R. R.;Ntokou, Aglaia;Gallardo-Vara, Eunate;Aryal, Binod;Rotllan, Noemi;Garcia-Milian, Rolando;Hwa, John;Kluger, Yuval;Martin, Kathleen A. A.;Fernandez-Hernando, Carlos;Greif, Daniel M. M.
- 通讯作者:Greif, Daniel M. M.
Targeting smooth muscle cell phenotypic switching in vascular disease.
- DOI:10.1016/j.jvssci.2021.04.001
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Chakraborty R;Chatterjee P;Dave JM;Ostriker AC;Greif DM;Rzucidlo EM;Martin KA
- 通讯作者:Martin KA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathleen Ann Martin其他文献
Kathleen Ann Martin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathleen Ann Martin', 18)}}的其他基金
Vascular Discovery, From Genes to Medicine 2023
血管发现,从基因到医学 2023
- 批准号:
10683501 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
2022 Vascular Discovery: From Genes to Medicine
2022 年血管发现:从基因到医学
- 批准号:
10469131 - 财政年份:2022
- 资助金额:
$ 53.45万 - 项目类别:
Novel insights into intimal hyperplasia in cardiac allograft vasculopathy
对心脏同种异体移植血管病中内膜增生的新见解
- 批准号:
10090623 - 财政年份:2018
- 资助金额:
$ 53.45万 - 项目类别:
Epigenetic control of vascular smooth muscle in cardiovascular disease
心血管疾病中血管平滑肌的表观遗传控制
- 批准号:
8761918 - 财政年份:2014
- 资助金额:
$ 53.45万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
8998052 - 财政年份:2014
- 资助金额:
$ 53.45万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
8630004 - 财政年份:2014
- 资助金额:
$ 53.45万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
8798690 - 财政年份:2014
- 资助金额:
$ 53.45万 - 项目类别:
Regulation of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的调节
- 批准号:
9211370 - 财政年份:2014
- 资助金额:
$ 53.45万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 53.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 53.45万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 53.45万 - 项目类别:
Discovery Grants Program - Individual